Review Ordered of Studies Using Celebrex, Bextra
The U.S. Food and Drug  Administration on Thursday ordered the review of preventative  studies involving Pfizer Inc.'s painkillers Celebrex and  Bextra, in light of recent evidence they may increase the risk  of heart attack and stroke.
Patients switching from Pfizer's branded cholesterol pill Lipitor to Merck & Co's Zocor -- now available as a cheap generic -- are more likely to have a heart attack or die, according to a Pfizer-backed study.